{"id":8616,"date":"2025-10-01T09:44:26","date_gmt":"2025-10-01T07:44:26","guid":{"rendered":"https:\/\/www.bioga.org\/debiopharm-adquiere-la-licencia-del-anticuerpo-biespecifico-her3-her2-de-sunrock-biopharma-para-desarrollar-el-adc-debio-2512\/"},"modified":"2026-04-15T12:22:00","modified_gmt":"2026-04-15T10:22:00","slug":"debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc","status":"publish","type":"post","link":"https:\/\/www.bioga.org\/en\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\/","title":{"rendered":"Debiopharm acquires the license for SunRock Biopharma&#8217;s bispecific HER3\/HER2 antibody to develop the Debio 2512 ADC"},"content":{"rendered":"<h6><strong>Lausanne (Switzerland) and Santiago de Compostela (Spain) \u2013 September 30, 2025 \u2013 Privately held Swiss biopharmaceutical company Debiopharm has signed a licensing agreement with SunRock Biopharma to develop SRB21, a bispecific antibody against HER3 and HER2. SunRock, a Galician company supported by the Xunta de Galicia through Xesgalicia, specializes in developing antibodies against highly invasive tumors with urgent clinical needs.<\/strong><\/h6>\n<p>With this agreement, Debiopharm will exercise its license option on SRB21 to combine it with its proprietary MultiLINK\u2122 Linker technology and create a new antibody-drug conjugate (ADC), which will be marketed under the name Debio 2512.<br \/>\nToward the next generation of ADCs<\/p>\n<p>Debiopharm will apply its \u201cTrifecta\u201d strategy\u2014strategic target selection, innovative linkers, and intelligent choice of cytotoxic payloads\u2014to design a precision ADC. Bispecific ADCs have the potential to increase treatment efficacy and specificity by targeting two antigens simultaneously, reduce adverse effects, and overcome resistance mechanisms.<\/p>\n<p>\u201cBispecific ADCs are one of the most promising approaches in oncology,\u201d said Bertrand Ducrey, CEO of Debiopharm. \u201cThis license allows us to apply our MultiLINK\u2122 technology to a dual design that could pave the way for revolutionary therapies for HER-driven cancers.\u201d<\/p>\n<p>HER2-driven tumors are associated with more aggressive growth, early relapses, and greater resistance to treatment. Although current therapies have led to significant advances, many patients eventually develop resistance and metastasis, limiting the durability of the response and long-term survival benefits. By simultaneously targeting HER2 and HER3, SRB21 could overcome this resistance and prolong clinical response.<\/p>\n<p>\u201cThe licensing of SRB21 is a strategic milestone for SunRock Biopharma and a validation of our bispecific antibody platform,\u201d said Laureano Sim\u00f3n, CEO of SunRock. \u201cWith Debiopharm, we aim to accelerate the development of next-generation ADCs that offer new opportunities for patients with HER2-resistant tumors.\u201d<\/p>\n<p>\u201cPatients with HER2-positive cancers require therapies capable of anticipating and overcoming tumor resistance,\u201d added Fr\u00e9d\u00e9ric Levy, CSO of Debiopharm. \u201cOur \u2018Trifecta\u2019 approach, combined with a bispecific HER3\/HER2 antibody, represents a very promising advance in treating difficult-to-treat tumors.\u201d<\/p>\n<p><strong>Debiopharm\u2019s ADC Experience<\/strong><br \/>\nWe are developing fit-for-purpose antibody-drug conjugates using a customized \u201cTrifecta\u201d approach: strategic target selection, innovative patented MultiLINK\u2122 linker technology, and intelligent choice of therapeutic loads.<\/p>\n<p>The Swiss company boasts a robust portfolio of anti-drug conjugates (ADCs), including Debio 1562M (anti-CD37, in clinical trials for acute myeloid leukemia and myelodysplastic syndromes) and Debio 0532 (anti-HER3 for solid tumors), in addition to programs in development against undisclosed targets. Its in-house expertise spans conjugation and PK\/PD optimization to toxicology, clinical development, and supply chain management.<\/p>\n<p><strong>About SunRock Biopharma<\/strong><br \/>\nSunRock Biopharma develops first-class, bispecific therapeutic antibodies against innovative targets such as CCR9 and recognized targets such as HER3. Its shareholders include the EAF Spain \u2013 Isabel la Cat\u00f3lica Fund (EIF) and XesGalicia, the investment arm of the Xunta de Galicia (Galician Regional Government).<\/p>\n<p><strong>About Debiopharm<\/strong><br \/>\nDebiopharm develops innovative therapies in oncology and infectious diseases. It identifies high-potential compounds, tests their safety and efficacy in clinical settings, and collaborates with global pharmaceutical companies to maximize patient access to these therapies.<\/p>\n<p>More info: www.debiopharm.com<\/p>\n<p>Follow us on X: @DebiopharmNews<\/p>\n<p>LinkedIn: www.linkedin.com\/company\/debiopharminternational\/<\/p>\n<p>Press Contact:<\/p>\n<p>Dawn Bonine \u2013 Head of Communications<\/p>\n<p>dawn.bonine@debiopharm.com<\/p>\n<p>Tel: +41 (0)21 321 01 11<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lausanne (Switzerland) and Santiago de Compostela (Spain) \u2013 September 30, 2025 \u2013 Privately held Swiss biopharmaceutical company Debiopharm has signed a&#8230;<\/p>\n","protected":false},"author":5,"featured_media":7624,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[53],"tags":[],"class_list":["post-8616","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categorizar-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Debiopharm acquires the license for SunRock Biopharma&#039;s bispecific HER3\/HER2 antibody to develop the Debio 2512 ADC | Bioga<\/title>\n<meta name=\"description\" content=\"Bioga es el Cluster Tecnol\u00f3xico Empresarial das Ciencias da Vida de Galicia. La voz de la industria Biotech Gallega.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.bioga.org\/en\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Debiopharm acquires the license for SunRock Biopharma&#039;s bispecific HER3\/HER2 antibody to develop the Debio 2512 ADC | Bioga\" \/>\n<meta property=\"og:description\" content=\"Bioga es el Cluster Tecnol\u00f3xico Empresarial das Ciencias da Vida de Galicia. La voz de la industria Biotech Gallega.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.bioga.org\/en\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\/\" \/>\n<meta property=\"og:site_name\" content=\"Bioga\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/BiogaGalicia\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-01T07:44:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T10:22:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.bioga.org\/wp-content\/uploads\/2025\/10\/Imagen-de-WhatsApp-2025-09-30-a-las-16.34.28_bb6a290e.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"1196\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Elena\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BiogaGalicia\" \/>\n<meta name=\"twitter:site\" content=\"@BiogaGalicia\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Elena\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\\\/\"},\"author\":{\"name\":\"Elena\",\"@id\":\"https:\\\/\\\/www.bioga.org\\\/#\\\/schema\\\/person\\\/a3894d579744eaeceaac6f790f3dc413\"},\"headline\":\"Debiopharm acquires the license for SunRock Biopharma&#8217;s bispecific HER3\\\/HER2 antibody to develop the Debio 2512 ADC\",\"datePublished\":\"2025-10-01T07:44:26+00:00\",\"dateModified\":\"2026-04-15T10:22:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\\\/\"},\"wordCount\":539,\"publisher\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.bioga.org\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Imagen-de-WhatsApp-2025-09-30-a-las-16.34.28_bb6a290e.jpg\",\"articleSection\":[\"Sin categorizar\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\\\/\",\"url\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\\\/\",\"name\":\"Debiopharm acquires the license for SunRock Biopharma's bispecific HER3\\\/HER2 antibody to develop the Debio 2512 ADC | Bioga\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.bioga.org\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Imagen-de-WhatsApp-2025-09-30-a-las-16.34.28_bb6a290e.jpg\",\"datePublished\":\"2025-10-01T07:44:26+00:00\",\"dateModified\":\"2026-04-15T10:22:00+00:00\",\"description\":\"Bioga es el Cluster Tecnol\u00f3xico Empresarial das Ciencias da Vida de Galicia. La voz de la industria Biotech Gallega.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.bioga.org\\\/en\\\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.bioga.org\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Imagen-de-WhatsApp-2025-09-30-a-las-16.34.28_bb6a290e.jpg\",\"contentUrl\":\"https:\\\/\\\/www.bioga.org\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Imagen-de-WhatsApp-2025-09-30-a-las-16.34.28_bb6a290e.jpg\",\"width\":1600,\"height\":1196},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Debiopharm acquires the license for SunRock Biopharma&#8217;s bispecific HER3\\\/HER2 antibody to develop the Debio 2512 ADC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.bioga.org\\\/#website\",\"url\":\"https:\\\/\\\/www.bioga.org\\\/\",\"name\":\"Bioga\",\"description\":\"Cl\u00faster Tecnol\u00f3xico Empresarial das Ciencias da Vida\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.bioga.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.bioga.org\\\/#organization\",\"name\":\"Bioga\",\"url\":\"https:\\\/\\\/www.bioga.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.bioga.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.bioga.org\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/bioga-logo-color-lg.svg\",\"contentUrl\":\"https:\\\/\\\/www.bioga.org\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/bioga-logo-color-lg.svg\",\"width\":121,\"height\":41,\"caption\":\"Bioga\"},\"image\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/BiogaGalicia\\\/\",\"https:\\\/\\\/x.com\\\/BiogaGalicia\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/\",\"https:\\\/\\\/www.instagram.com\\\/biogagalicia\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.bioga.org\\\/#\\\/schema\\\/person\\\/a3894d579744eaeceaac6f790f3dc413\",\"name\":\"Elena\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3151168f9f01666f7f93316dde68ce2198065faa392b2e8a9281ac1a114599e6?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3151168f9f01666f7f93316dde68ce2198065faa392b2e8a9281ac1a114599e6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3151168f9f01666f7f93316dde68ce2198065faa392b2e8a9281ac1a114599e6?s=96&d=mm&r=g\",\"caption\":\"Elena\"},\"url\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/author\\\/elenabioga-org\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Debiopharm acquires the license for SunRock Biopharma's bispecific HER3\/HER2 antibody to develop the Debio 2512 ADC | Bioga","description":"Bioga es el Cluster Tecnol\u00f3xico Empresarial das Ciencias da Vida de Galicia. La voz de la industria Biotech Gallega.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.bioga.org\/en\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\/","og_locale":"en_US","og_type":"article","og_title":"Debiopharm acquires the license for SunRock Biopharma's bispecific HER3\/HER2 antibody to develop the Debio 2512 ADC | Bioga","og_description":"Bioga es el Cluster Tecnol\u00f3xico Empresarial das Ciencias da Vida de Galicia. La voz de la industria Biotech Gallega.","og_url":"https:\/\/www.bioga.org\/en\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\/","og_site_name":"Bioga","article_publisher":"https:\/\/www.facebook.com\/BiogaGalicia\/","article_published_time":"2025-10-01T07:44:26+00:00","article_modified_time":"2026-04-15T10:22:00+00:00","og_image":[{"width":1600,"height":1196,"url":"https:\/\/www.bioga.org\/wp-content\/uploads\/2025\/10\/Imagen-de-WhatsApp-2025-09-30-a-las-16.34.28_bb6a290e.jpg","type":"image\/jpeg"}],"author":"Elena","twitter_card":"summary_large_image","twitter_creator":"@BiogaGalicia","twitter_site":"@BiogaGalicia","twitter_misc":{"Written by":"Elena","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.bioga.org\/en\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\/#article","isPartOf":{"@id":"https:\/\/www.bioga.org\/en\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\/"},"author":{"name":"Elena","@id":"https:\/\/www.bioga.org\/#\/schema\/person\/a3894d579744eaeceaac6f790f3dc413"},"headline":"Debiopharm acquires the license for SunRock Biopharma&#8217;s bispecific HER3\/HER2 antibody to develop the Debio 2512 ADC","datePublished":"2025-10-01T07:44:26+00:00","dateModified":"2026-04-15T10:22:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.bioga.org\/en\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\/"},"wordCount":539,"publisher":{"@id":"https:\/\/www.bioga.org\/#organization"},"image":{"@id":"https:\/\/www.bioga.org\/en\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.bioga.org\/wp-content\/uploads\/2025\/10\/Imagen-de-WhatsApp-2025-09-30-a-las-16.34.28_bb6a290e.jpg","articleSection":["Sin categorizar"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.bioga.org\/en\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\/","url":"https:\/\/www.bioga.org\/en\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\/","name":"Debiopharm acquires the license for SunRock Biopharma's bispecific HER3\/HER2 antibody to develop the Debio 2512 ADC | Bioga","isPartOf":{"@id":"https:\/\/www.bioga.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.bioga.org\/en\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\/#primaryimage"},"image":{"@id":"https:\/\/www.bioga.org\/en\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.bioga.org\/wp-content\/uploads\/2025\/10\/Imagen-de-WhatsApp-2025-09-30-a-las-16.34.28_bb6a290e.jpg","datePublished":"2025-10-01T07:44:26+00:00","dateModified":"2026-04-15T10:22:00+00:00","description":"Bioga es el Cluster Tecnol\u00f3xico Empresarial das Ciencias da Vida de Galicia. La voz de la industria Biotech Gallega.","breadcrumb":{"@id":"https:\/\/www.bioga.org\/en\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.bioga.org\/en\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bioga.org\/en\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\/#primaryimage","url":"https:\/\/www.bioga.org\/wp-content\/uploads\/2025\/10\/Imagen-de-WhatsApp-2025-09-30-a-las-16.34.28_bb6a290e.jpg","contentUrl":"https:\/\/www.bioga.org\/wp-content\/uploads\/2025\/10\/Imagen-de-WhatsApp-2025-09-30-a-las-16.34.28_bb6a290e.jpg","width":1600,"height":1196},{"@type":"BreadcrumbList","@id":"https:\/\/www.bioga.org\/en\/debiopharm-acquires-the-license-for-sunrock-biopharmas-bispecific-her3her2-antibody-to-develop-the-debio-2512-adc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.bioga.org\/en\/"},{"@type":"ListItem","position":2,"name":"Debiopharm acquires the license for SunRock Biopharma&#8217;s bispecific HER3\/HER2 antibody to develop the Debio 2512 ADC"}]},{"@type":"WebSite","@id":"https:\/\/www.bioga.org\/#website","url":"https:\/\/www.bioga.org\/","name":"Bioga","description":"Cl\u00faster Tecnol\u00f3xico Empresarial das Ciencias da Vida","publisher":{"@id":"https:\/\/www.bioga.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.bioga.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.bioga.org\/#organization","name":"Bioga","url":"https:\/\/www.bioga.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bioga.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.bioga.org\/wp-content\/uploads\/2022\/06\/bioga-logo-color-lg.svg","contentUrl":"https:\/\/www.bioga.org\/wp-content\/uploads\/2022\/06\/bioga-logo-color-lg.svg","width":121,"height":41,"caption":"Bioga"},"image":{"@id":"https:\/\/www.bioga.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/BiogaGalicia\/","https:\/\/x.com\/BiogaGalicia","https:\/\/www.linkedin.com\/company\/","https:\/\/www.instagram.com\/biogagalicia\/"]},{"@type":"Person","@id":"https:\/\/www.bioga.org\/#\/schema\/person\/a3894d579744eaeceaac6f790f3dc413","name":"Elena","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/3151168f9f01666f7f93316dde68ce2198065faa392b2e8a9281ac1a114599e6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3151168f9f01666f7f93316dde68ce2198065faa392b2e8a9281ac1a114599e6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3151168f9f01666f7f93316dde68ce2198065faa392b2e8a9281ac1a114599e6?s=96&d=mm&r=g","caption":"Elena"},"url":"https:\/\/www.bioga.org\/en\/author\/elenabioga-org\/"}]}},"_links":{"self":[{"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/posts\/8616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/comments?post=8616"}],"version-history":[{"count":2,"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/posts\/8616\/revisions"}],"predecessor-version":[{"id":8618,"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/posts\/8616\/revisions\/8618"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/media\/7624"}],"wp:attachment":[{"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/media?parent=8616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/categories?post=8616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/tags?post=8616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}